Iodine I 124 Evuzamitide clinical trials
How each study uses Iodine I 124 Evuzamitide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Iodine I 124 Evuzamitide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
University of Tennessee Graduate School of Medicine (2) · Attralus, Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses Iodine I 124 Evuzamitide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid LoadRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06974877Written as 124I AT-01
- Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid LoadCompletedPhase 2University of Tennessee Graduate School of MedicineNCT05968846Written as Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
- A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic AmyloidosisCompletedPhase 2Attralus, Inc.NCT05235269Written as 124I-AT-01
- 124I-p5+14 Injection Safety in Subjects With Systemic AmyloidosisCompletedPhase 1/2University of Tennessee Graduate School of MedicineNCT03678259Written as 124I-p5+14 Injection
Codes
What other systems call Iodine I 124 Evuzamitide · ClinicalTrials.gg INT015849
- UNII (FDA) 9DR4VH0DJPIODINE I-124 EVUZAMITIDEOne source FDA
- NCI Thesaurus C184877Iodine I 124 EvuzamitideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9DR4VH0DJP | IODINE I-124 EVUZAMITIDE | One source FDA |
| NCI Thesaurus | C184877 | Iodine I 124 Evuzamitide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.